Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2020.191137.
Ewing's sarcoma (ES) is a prevalent bone malignancy. It is critical to explore new diagnostic and prognostic indicators because of the rapid progression of ES and the low survival rate of metastatic ES patients. However, few parameters of clinical significance have been found. The aim of this study was to establish a new classifier with clinical laboratory data to help ES detection and prognosis prediction.
A total of 135 ES patients, 150 healthy individuals, and 228 patients with primary benign bone lesions were included. Logistic regression on clinical laboratory indicators was conducted to establish the classifier, and then the classifier was assessed by drawing the receiver operating characteristic (ROC) curves. Patient survival was evaluated using the Kaplan-Meier method.
We established the diagnostic classifier, called Ces, with clinical laboratory indicators to distinguish ES from healthy individuals. Ces showed great diagnostic performance in the test cohort (area under the receiver operating characteristic curve (AUC) 0.95) and could identify early-stage (AUC 0.93) and small-size (AUC 0.95) ES effectively. In addition, the classifier had good ability to differentiate ES from primary benign bone lesions (AUC 0.77 for Ces, AUC 0.83 for Ces + age). Furthermore, Ces was associated with tumor metastasis and event-free survival (EFS) of ES patients and showed better performance than lactate dehydrogenase (LDH) in prognosis prediction.
Our study indicates that Ces has the potential to be a non-invasive biomarker for ES diagnosis and prognosis.
尤因氏肉瘤（ES）是一种常见的骨恶性肿瘤。由于 ES 的快速进展和转移性 ES 患者的生存率低，探索新的诊断和预后指标至关重要。然而，很少发现具有临床意义的参数。本研究旨在建立一个新的基于临床实验室数据的分类器，以帮助 ES 的检测和预后预测。
共纳入 135 例 ES 患者、150 例健康个体和 228 例原发性良性骨病变患者。对临床实验室指标进行逻辑回归以建立分类器，然后通过绘制接收者操作特征（ROC）曲线评估分类器。采用 Kaplan-Meier 方法评估患者的生存情况。
我们建立了一个称为 Ces 的诊断分类器，利用临床实验室指标来区分 ES 与健康个体。Ces 在测试队列中表现出出色的诊断性能（ROC 曲线下面积（AUC）为 0.95），能够有效地识别早期（AUC 为 0.93）和小尺寸（AUC 为 0.95）的 ES。此外，该分类器能够很好地区分 ES 与原发性良性骨病变（Ces 的 AUC 为 0.77，Ces + 年龄的 AUC 为 0.83）。此外，Ces 与 ES 患者的肿瘤转移和无事件生存（EFS）相关，并在预后预测方面表现优于乳酸脱氢酶（LDH）。
我们的研究表明，Ces 有可能成为 ES 诊断和预后的非侵入性生物标志物。
